MaxCyte reports strong fourth quarter as full-year revenues fall
13th Mar 2024 12:04
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.
Read moreMaxCyte flags lower 2023 revenue, flat 2024 growth
5th Mar 2024 13:01
(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.
Read moreMaxCyte flags uptick in total fourth-quarter revenue
9th Jan 2024 08:55
(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.
Read moreMaher Masoud starts as MaxCyte president, CEO
2nd Jan 2024 11:25
(Sharecast News) - MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.
Read moreMaxCyte announces new CEO, updates revenue guidance
12th Dec 2023 13:46
(Sharecast News) - Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.
Read moreMaxCyte joins Alliance for mRNA Medicines
16th Nov 2023 13:57
(Sharecast News) - Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday.
Read moreMaxCyte lowers full-year guidance after weaker third quarter
5th Oct 2023 13:00
(Sharecast News) - Cell engineering specialist MaxCyte revised its full-year guidance downwards on Thursday based on its preliminary third-quarter revenue.
Read moreMaxCyte signs licence deal with Vittoria Biotherapeutics
10th Jul 2023 13:20
(Sharecast News) - MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.
Read moreMaxCyte inks platform licensing deal with Lyell
6th Jul 2023 14:49
(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.
Read moreMaxCyte revises guidance after weaker first quarter
11th May 2023 12:10
(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.
Read moreMaxCyte installs Douglas Swirsky as its new finance chief
28th Mar 2023 13:03
(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.
Read moreMaxCyte expecting strong 2023 after decent results
16th Mar 2023 15:01
(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.
Read moreMaxCyte flags 2022 revenue growth, sets new guidance
7th Mar 2023 09:32
(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.
Read moreMaxCyte signs strategic platform licence with Catamaran Bio
4th Jan 2023 07:45
(Sharecast News) - Commercial cell engineering company MaxCyte announced the signing of a strategic platform licence (SPL) with Catamaran Bio on Wednesday.
Read moreMaxCyte inks deal with South Korea's Curamys
5th Dec 2022 13:28
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence with South Korea-based biotechnology specialist Curamys on Monday, which develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Read more